奥拉西坦胶囊防治乳腺癌化疗相关性认知功能障碍的疗效观察

Clinical efficacy of oxiracetam capsules on chemotherapy-induced cognitive impairment in breast cancer

目的:观察奥拉西坦胶囊防治乳腺癌化疗相关性认知功能障碍的临床疗效。方法:选取2014年02月至2016年10月在我科行乳腺癌改良根治术术后辅助化疗的患者共98例,随机分为实验组和对照组各49例,两组均行术后辅助化疗,实验组在对照组的基础上加用奥拉西坦胶囊(2粒/次、3次/日,化疗期间及化疗间歇期间均坚持服用),于化疗第4周期入院时及第6周期结束后(1～2周内)分别接受简易精神状态量表(MMSE)评分、日常生活能力表(ADL)评分。结果:第6周期化疗结束后,实验组MMSE评分的降低幅度均较对照组低,与对照组比较差异有统计学意义(P <0. 05);实验组ADL评分的升高幅度较对照组低,与对照组比较差异有统计学意义(P <0. 05)。结论:奥拉西坦可以改善化疗相关性认知障碍,值得在临床中进一步研究和推广运用。

Objective To observe the clinical efficacy of oxiracetam capsules on chemotherapy-induced cognitive impairment in breast cancer. Methods： A total of 98 patients were randomly divided into experiment group and control group of 49 cases,both groups were postoperative adjuvant chemotherapy.The experiment group was treated with oxiracetam capsules on the basis of the control group （2 pills each time,3 times a day,and during chemothrapy and in chemotherapy intermittent period,both insist on taking）.In the fourth week of chemotherapy and after the end of the 6th week（1~2 weeks）,scores of MMSE and ADL were evaluated. Results： After the sixth cycle of chemotherapy,the MMSE score reduction extent of the experiment group was lower than that of the control group,with statistically significant（ P 〈0.05）.The increase extent of the ADL score in the experiment group was lower than that in the control group,with statistically significant （ P 〈0.05）. Conclusion： Oxiracetam capsules can significantly reduce chemotherapy-induced cognitive impairment in breast cancer,worthy of further clinical research.